Beta Bionics, INC 10-Q quarterly reports

Beta Bionics reports a 38% increase in Q2 net sales driven by single-use product growth, but net loss also widens due to increased operating expenses.

Beta Bionics reports Q1 2026 net sales of $27.6 million, driven by growth in iLet adoption and recurring revenue from single-use products.

Beta Bionics, Inc. announced significant revenue growth and new patient adoption for its iLet Bionic Pancreas, alongside increased operating expenses and net losses, as it continues to invest heavily in commercialization and R&D.

Beta Bionics, a medical device company specializing in diabetes management, announced significant revenue and patient growth for the second quarter and first half of 2025, driven by increased adoption of its iLet Bionic Pancreas, while continuing to incur substantial net losses due to ongoing investments in commercialization and product development.

Beta Bionics reports increased revenue in Q1 2025, fueled by growing adoption of its iLet Bionic Pancreas system.